Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte essential for nerve impulse transmission, muscle contraction, and maintaining intracellular fluid volume and acid-base balance. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Adjunct therapy in diabetic ketoacidosis. ## Adult Dosing * **Oral:** * **Treatment of hypokalemia:** Typically 20-100 mEq/day divided into 2-4 doses. Lower doses may be used for prevention or mild deficiency. Maximum daily dose is generally 200 mEq. * **Prevention of hypokalemia:** Typically 10-40 mEq/day. * **Intravenous:** Dosing depends on the severity of hypokalemia and patient status. Precise dosing and infusion rate are critical and often guided by institutional protocols or specific laboratory values. * **Mild to moderate hypokalemia (serum K+ 3.0-3.4 mEq/L):** May be treated orally. If IV is necessary, infusion rates typically do not exceed 10 mEq/hour, and concentration should not exceed 40 mEq/L to minimize phlebitis and cardiac risk. Total daily dose usually 20-40 mEq. * **Severe hypokalemia (serum K+ < 3.0 mEq/L) or symptomatic hypokalemia:** May require IV administration at higher rates (up to 20 mEq/hour, rarely higher) and concentrations (up to 80 mEq/L in critical care settings with cardiac monitoring), but only in a critical care setting with continuous cardiac monitoring. Total daily dose can exceed 100 mEq. ## Pediatric Dosing * **Oral:** * **Treatment of hypokalemia:** 2-5 mEq/kg/day divided into 2-4 doses. Maximum daily dose is typically 20 mEq/kg/day or 300 mEq/day, whichever is less. * **Prevention of hypokalemia:** 1 mEq/kg/day. * **Intravenous:** Dosing and infusion rates are highly individualized and based on serum potassium levels, patient weight, and clinical status. Generally, infusion rates should not exceed 0.5 mEq/kg/hour (max 10 mEq/hour in neonates, 20 mEq/hour in older children). Concentrations typically limited to 40 mEq/L in peripheral lines and up to 80 mEq/L in central lines, with continuous cardiac monitoring for rates > 0.3 mEq/kg/hr or concentrations > 40 mEq/L. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium accumulation can lead to hyperkalemia. Dosing must be carefully titrated and serum electrolytes closely monitored. In severe renal impairment, potassium supplementation may be contraindicated. ## Contraindications * Severe renal impairment. * Conditions that predispose to hyperkalemia (e.g., Addison's disease, untreated Addison's disease, chronic dehydration, extensive tissue injury, certain medications like ACE inhibitors, ARBs, potassium-sparing diuretics). * Hyperkalemia. * History of allergy to potassium chloride or any component of the formulation. * Gastric stasis or delayed gastric emptying (for oral solid dosage forms). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence (oral). * **Serious:** * **Hyperkalemia:** Can manifest as muscle weakness, paralysis, paresthesias, cardiac arrhythmias (including bradycardia, heart block, ventricular fibrillation, cardiac arrest), and hypotension. * **Gastrointestinal:** Esophageal, gastric, or intestinal ulceration, perforation, or bleeding, especially with undissolved tablets or rapid infusion. * **Venous irritation, phlebitis** (IV). ## Key Drug Interactions * **ACE inhibitors, ARBs, Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), NSAIDs, Cyclosporine, Tacrolimus, Heparin:** Increased risk of hyperkalemia. * **Diuretics (non-potassium-sparing):** Can increase potassium loss, requiring potassium supplementation. * **Sodium Polystyrene Sulfonate:** May decrease absorption of oral potassium. * **Neuromuscular Blocking Agents:** Increased risk of hyperkalemia and prolonged neuromuscular blockade. ## Monitoring * **Serum potassium levels:** Frequently, especially during initiation of therapy, dose changes, IV administration, and in patients with renal impairment or conditions predisposing to hyperkalemia. * **Renal function (BUN, creatinine):** Baseline and periodically. * **ECG:** Particularly with rapid IV infusion or suspected hyperkalemia. * **Signs and symptoms of hypokalemia and hyperkalemia:** Muscle weakness, cramps, fatigue, palpitations, nausea, vomiting. ## Clinical Pearls * Oral potassium chloride tablets should be taken with meals or immediately after, with a full glass of water, to minimize gastrointestinal irritation. * When administering IV potassium chloride, always dilute and infuse slowly, never as a bolus. Continuous cardiac monitoring is essential for infusions exceeding 10 mEq/hour or in patients with ECG changes or severe hypokalemia. * The solid oral dosage forms (tablets, capsules) are often associated with higher rates of GI adverse effects than liquid or effervescent formulations. * Be aware that many salt substitutes contain potassium chloride and can contribute to potassium intake. *This information is intended for clinical use only. Always verify current prescribing information, including contraindications, warnings, precautions, drug interactions, and adverse effects, with the official product labeling or a reliable drug information resource before dispensing or administering.*